Absence of an active metabolite for the triazole antifungal pramiconazole

Acta Dermato-Venereologica

Volumn 87, Issue 1, 2007, Pages 22-26

  Ausma, Jannie ^a   Pennick, Gennethel ^b   Bohets, Hilde ^c   Van De Velde, Vera ^d   Borgers, Marcel ^a,e   Fothergill, Annette ^b  

^a Barrier Therapeutics NV   (Belgium)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Barrier Therapeutics   (United States)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Dermatophyte; Inhibition zone bioassay; Metabolism; R126638; Yeast

Indexed keywords

ANTIFUNGAL AGENT; DRUG METABOLITE; PLACEBO; PRAMICONAZOLE; UNCLASSIFIED DRUG;

AGAR GEL DIFFUSION; ANTIFUNGAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANTIFUNGAL AGENTS; HUMANS; IMIDAZOLES; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 33846884215     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0179     Document Type: Article

References (20)

1. Odds F, Ausma J, Van Gerven F, Woestenborghs, Meerpoel L, Heerens J, et al. Activity in vitro and in vivo of a novel azole antifungal agent R126638 Antimicrob Agents Chemother 2004; 43: 388-391.
2. Vanden Bossche H, Ausma J, Bohets H, Vermuyten K, Willemsens G, Marichal P, et al. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp. and Microsporum canis. Antimicrob Agents Chemother 2004; 48: 3272-3278.
3. Moshage H, Yap SH. Primary cultures of human hepatocytes: a unique system for studies in toxicology, virology, parasitology and liver pathophysiology in man. J Hepatol 1992; 15: 404-413.
4. Hostetler JS, Heykants J, Clemons KV, Woestenborghs R, Hanson LH, Stevens DA. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient varieties in concentrations. Antimicrob Agents Chemother 1993; 37: 2224-2227.
5. Hülsewede JW, Dermmouni H, Ansorg R. Determination of itraconazole and hydroxy-itraconazole in sera using high-performance liquid chromatography and a bioassay. Zentralbl Bakteriol 1995; 282: 457-464.
6. Odds FC, Dupont B, Rinaldi MG, Stevens DA, Warnock DW, Woestenborghs R. Bioassay for itraconazole blood levels: an interlaboratory collaborative study. Antimicrob Chemother 1999; 43: 723-727.
7. Ausma J, Bruynseels J, Snoeck E, Blockhuys S, van Rossem K, Borgers M. Placebo-controlled randomized double-blind multiple dose dose-rising trial in healthy volunteers to assess the tolerability, safety and pharmacokinetics of the novel antifungal R126638. J Eur Acad Derm Venereol 2004; 18 (suppl. 2): 392.
8. Bohets H, Lavrijsen K, Hendrickx J, Van Houdt J, van Genechten V, Verboven P, et al. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol 2000; 129: 1655-1667.
9. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenon reagent. J Biol Chem 1951; 193: 265-275.
10. Miller GL. Protein determination for large number samples. Anal Chem 1959; 31: 964.
11. Omura T, Sato R. The carbon monoxide pigment of liver microsomes. II. Solubilization, purification and properties. J Biol Chem 1964; 239: 2379-2385.
12. 2+ on enzymatic dispersion of isolated perfused liver. Exp Cell Res 1972; 74: 450-454.
13. Reese JA, Byard JL. Isolation and culture of adult hepatocytes from liver biopsies. In Vitro 1981; 17: 935-940.
14. Bodet CA, Jorgensen JH, Drutz DJ. Simplified bioassay method for measurement of flucytosine or ketoconazole. J Clin Microbiol 1985; 22: 157-160.
15. Shah V, Midha K, Dighe S, McGilveray I, Skelly J, Yacobi A, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharmaceutical Sci 1992; 81: 309-312.
16. Guidance for Industry. Bioanalytical method validation. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), May 2001.
17. Gascoigne EW, Barton GJ, Michaels M, Meuldermans W, Heykants J. The kinetics of ketoconazole in animals and man. Clin Res Rev 1981; 1: 177-187.
18. Feczko J: Fluconazole: an overview; In: Fluconazole and its role in vaginal candidiasis. Richardson RG, ed. International Congress and Symposium Series No. 160. London: Royal Society of Medicine Services, 1989: p. 11-18.
19. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos. 2004; 32: 1121-1131.
20. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycosis 1989; 32 (suppl 1): 67-87.